Parecoxib

A prodrug form of valdecoxib

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
25mg

￥762.00

610.00

- +
50mg

￥1300.00

1040.00

- +
100mg

￥2175.00

1740.00

- +
200mg

￥0.00

0.00

- +
500mg

￥0.00

0.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Background

Parecoxib is a prodrug form of the COX-2 inhibitor valdecoxib .¹ It is converted to valdecoxib by human liver microsomes in vitro and in vivo in rats, dogs, and cynomolgous monkeys. Parecoxib is also a cannabinoid (CB) receptor 1 agonist with an EC₅₀ value of 2.4 ?M in HEK293 cells.² It reduces hyperalgesia in a rat model of carrageenan-induced foot pad edema (ED₅₀ = 5 mg/kg) and decreases inflammation in a rat model of M. butyricum-induced arthritis (ED₅₀ = 0.08 mg/kg).¹

1.Talley, J.J., Bertenshaw, S.R., Brown, D.L., et al.N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administrationJ. Med. Chem.43(9)1661-1663(2000) 2.Schr?der, H., H?llt, V., and Becker, A.Parecoxib and its metabolite valdecoxib directly interact with cannabinoid binding sites in CB1-expressing HEK 293 cells and rat brain tissueNeurochem. Int.58(1)9-13(2011)